VisEn Medical introduced its new FAST (Fluorescent Activatible Sensor Technology) imaging agent platform for imaging disease-associated biomarkers and drug response in vivo at the annual scientific sessions of the American Association of Cancer Research (AACR) annual meeting in Denver.

FAST imaging agents are smaller molecule, biocompatible, activatible fluorescent agents that combine increased biomarker specificity with accelerated pharmacokinetics for advanced measurement and monitoring of key disease biomarkers in vivo, the company said.

"VisEn's new FAST agent platform will enable yet another level of imaging performance and versatility by providing increased ranges of biomarker specificity with faster pharmacokinetic profiles," said Kirtland Poss, president and CEO of VisEn. "This enables more versatility in pre-clinical study designs, greater breadth of imaging data and even more biomarker multiplexing for our customers, especially in longitudinal studies of disease progression and therapeutic response."